Plasma PD-L1 as a biomarker in the clinical management of glioblastoma multiforme—a retrospective cohort study

BACKGROUND AND OBJECTIVES: Glioblastoma multiforme (GBM) is the most aggressive, malignant, and therapy-resistant tumor of the brain. Blockade therapy targeting the programmed cell death protein 1 (PD-1)/programmed death ligand (PD-L1) axis is currently under investigation for the clinical managemen...

Descripción completa

Detalles Bibliográficos
Autores principales: Masood, Aetsam Bin, Batool, Sajida, Bhatti, Sajid Nazir, Ali, Asad, Valko, Marian, Jomova, Klaudia, Kuca, Kamil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387524/
https://www.ncbi.nlm.nih.gov/pubmed/37529045
http://dx.doi.org/10.3389/fimmu.2023.1202098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387524/
https://www.ncbi.nlm.nih.gov/pubmed/37529045
http://dx.doi.org/10.3389/fimmu.2023.1202098

Ejemplares similares